We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVET
201
DELISTED
Covetrus, Inc. Common Stock
CVET
$37K ﹤0.01%
+1,520
New +$43.8K
ABBV icon
202
PUT
AbbVie
ABBV
$450B
– –
-200
Closed -$9K
AMRX icon
203
Amneal Pharmaceuticals
AMRX
$5.7B
– –
-100,000
Closed -$1.42M
ANGO icon
204
AngioDynamics
ANGO
$558M
– –
-75,700
Closed -$1.73M
COR icon
205
Cencora
COR
$59.9B
– –
-250,398
Closed -$19.9M
KYNB
206
Kyntra Bio
KYNB
$29.3M
– –
-1,952
Closed -$2.65M
GILD icon
207
CALL
Gilead Sciences
GILD
$167B
– –
-600
Closed -$174K
LKFT
208
PUT
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
– –
-190
Closed -$23K
JNJ icon
209
Johnson & Johnson
JNJ
$609B
– –
-20,000
Closed -$2.8M
MRK icon
210
Merck
MRK
$315B
– –
-15,720
Closed -$1.25M
PBYI icon
211
Puma Biotechnology
PBYI
$434M
– –
-17,100
Closed -$663K
PINC
212
DELISTED
Premier
PINC
– –
-31,462
Closed -$1.08M
REGN icon
213
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-20,400
Closed -$8.38M
SRPT icon
214
Sarepta Therapeutics
SRPT
$1.82B
– –
-9,100
Closed -$1.08M
VTRS icon
215
Viatris
VTRS
$20.1B
– –
-122,000
Closed -$3.46M
WBA
216
DELISTED
Walgreens Boots Alliance
WBA
– –
-231,802
Closed -$14.7M
PRAH
217
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-149,507
Closed -$16.5M
PTLA
218
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-62,300
Closed -$2.16M
MDSO
219
DELISTED
Medidata Solutions, Inc.
MDSO
– –
-70,474
Closed -$5.16M
ARRY
220
DELISTED
Array Biopharma Inc
ARRY
– –
-48,200
Closed -$1.18M
5 6 7 8
9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.